Condition (MeSH)
Candidiasis, Chronic Mucocutaneous
ClinicalTrials.gov lists 5 trials for Candidiasis, Chronic Mucocutaneous or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Candidiasis, Chronic Mucocutaneous itself; the rest are tagged with a narrower condition beneath it.
When did Candidiasis, Chronic Mucocutaneous trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Candidiasis, Chronic Mucocutaneous trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Observational | 2 |
How many Candidiasis, Chronic Mucocutaneous trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 3 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Candidiasis, Chronic Mucocutaneous trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Matinas BioPharma Nanotechnologies, Inc. | 1 |
| Scynexis, Inc. | 1 |
Which serious adverse events do Candidiasis, Chronic Mucocutaneous trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Acute kidney injury | 7 | 1 |
| Respiratory failure | 7 | 2 |
| Diarrhoea | 6 | 1 |
| Pneumonia | 6 | 2 |
| Urinary tract infection | 6 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Candidiasis, Chronic Mucocutaneous? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Case report: Myocarditis in congenital STAT1 gain-of function. | Frontiers in immunology | 2023 | Yes |
| Efficacy of Cochleated Amphotericin B in Mouse and Human Mucocutaneous Candidiasis. | Antimicrobial agents and chemotherapy | 2022 | Yes |
| Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. | Blood | 2016 | Yes |
| STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. | The New England journal of medicine | 2011 | Yes |
| A homozygous CARD9 mutation in a family with susceptibility to fungal infections. | The New England journal of medicine | 2009 | Yes |
Showing 5 of 8 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Chronic mucocutaneous candidiasis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Chronic mucocutaneous candidiasis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Chronic mucocutaneous candidiasis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Chronic mucocutaneous candidiasis | 1334 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Chronic mucocutaneous candidiasis | 1334 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.